Sepracor, Inc. Announces Presentation Of LUNESTA(TM) Data At American Psychiatric Association Annual Meeting

MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 25, 2006--Sepracor Inc. (Nasdaq: SEPR - News) today announced that data from its Phase IIIB/IV studies of LUNESTA(TM) brand eszopiclone for the treatment of insomnia were presented at the annual meeting of the American Psychiatric Association in Toronto. The Effect of Eszopiclone 3 mg Compared with Placebo in Patients with Rheumatoid Arthritis (RA) and Co-Existing Insomnia

Back to news